Diabetic nephropathy and anemia: treatment considerations


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Представлены особенности тактики ведения, в т. ч. применения препаратов рекомбинантного человеческого эритропоэтина, при анемии у больных диабетической нефропатией

Full Text

Restricted Access

About the authors

T. P Demicheva

Email: DEMICH-PERM@MAIL.RU

References

  1. Шестакова М.В., Дедов И.И. Сахарный диабет и хроническая болезнь почек. М.: ООО “Медицинское информационное агентство”. 2009.
  2. Thomas M., MacIsaac J., Tsalamandris C. et al. Anemia in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 2004;89(9):4359—4363.
  3. Astor B., Muntner P., Levin A. еt al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988—1994). Arch. Intern. Med. 2002;162:1401-1408.
  4. Holland D.C. Predictors of hospitalization and death among predialysis patients: A retrospective cohort study. Nephrology Dialysis Transplantation 2000;15:650-658.
  5. Stevens P., O'Donogue D., Lameire N. Anemia in patients with diabetes: unrecognized, undetected and undetected? Curr. Med. Res. Opin. 2003; 19:395-401.
  6. Dries D., Sweitzer N., Drazner M. et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J. Am. Coll. Cardiol 2001; 38:421-428.
  7. Srivastava P., Thomas M., Calafiore P. et al. Diastolic dysfunction is associated with anemia in patients with type 2 diabetes. Clin. Sci. (Lond.)2006; 110:109-116.
  8. Carmargo J.L., Gross J.L. Conditions associated with very low values of glycohaemoglobin measured by an HPLC method. J Clin Pathology 2004; 57:346-349.
  9. McClellan W., Aronoff S., Bolton W. et al. The prevalence of anemia in patients with chronic kidney disease. Curr. Med. Res. Opin. 2004;20:1501-1510.
  10. Thomas M., Maclsaac R., Tsalamandris C. et al. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 2003; 26:1164-1169.
  11. Thomas M., Maclsaac R., Tsalamandris С. et al. The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrol. Dial. Transplant 2004;19:1792-1797.
  12. McClellan W., Aronoff S., Bolton W. et al. The prevalence of anemia in patients with chronic kidney disease. Curr.Med. Res. Opin. 2004;20:1501-1510.
  13. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with tyoe 2 diabetes. N. Engl. J. Med. 2008;358(24):2560-2572.
  14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovadcular and microvascular complications in type 2 diabetes: UKPDS 28. BMJ. 1998;317:703-713.
  15. EUCLID Study Group. Randomized placebo-controlled trial of lisinopril in normotensive patients with normotensive diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997;347:1787-1792.
  16. Brenner B.M., Cooper M.E., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001;345:861-869.
  17. Rusu A., Rusu F., Zalutchi D. et al. The influence of vitamin E supplementation on erythropoietin responsiveness in chronic hemodialysis patients with low levels of erythrocyte superoxide dismutase. Int. Urol. Nephrol. 2012 Apr 18. [Epub ahead of print]
  18. Konstantinopoulos P.A., Karamouzis M.V., Papavassiliou A.G. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: Time to reach the full therapeutic potential of erythropoietin. Biochim. Biophys. Acta. 2007; 1776:1-9.
  19. Ruifrok W.T., Boer R.A., Westenbrink B.D. et al. Erythropoietin in cardiac disease: New features of an old drug. Eur. J. Pharmacol. 2008; 585: 27.
  20. Cooij M.A., Groenendaal F., Kavelaars A. et al. Neuroprotective properties and mechanisms of erythropoietin in 'in vitro' and 'in vivo' experimental models rob hypoxia/ischemia. Brain. Res. Rev. 2008; 59:22-33.
  21. Sekiguchi N., Inoguchi T., Kobayashi K. et al. Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells. Biochem. Biophys Res. Commun. 2005;34:218-222.
  22. Quin C., Xiao Y., Zhong Q. et al. Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/ reoxygenation injury and the possible mechanism. Chin. J. Traumatol. 2008;11:352-358.
  23. Hirata A., Minamino T., Asanuma H. et al. Erythropoietin enhances Neovascularization of Ischemic Myocardial Infarction in Dogs. J. Am. Coll. Cardiol 2006; 48:176-184.
  24. McClellan W., Aronoff S., Bolton W. et al. The prevalence of anemia in patients with chronic kidney disease. Curr. Med. Res. Opin. 2004;20:1501-1510.
  25. Vaziri N.D., Zhou X.J. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol. Dial. Transplant. 2009;24:1082-1088.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies